Health Enhancement Products, Inc. Reveals Results From Canine Joint Health Study Conducted by Covance Inc.
May 05 2014 - 9:03AM
Marketwired
Health Enhancement Products, Inc. Reveals Results From Canine Joint
Health Study Conducted by Covance Inc.
KEEGO HARBOR, MI--(Marketwired - May 5, 2014) - Health
Enhancement Products, Inc. (OTCQB: HEPI), a Michigan-based biotech
firm investigating bioactive compounds extracted from algal
cultures, is pleased to announce preliminary research results for
efficacy in supporting canine joint health. The research was
conducted at Covance Inc., based in Princeton, New Jersey. Covance
is one of the world's largest contract research organizations and a
significant contributor to advances in animal
therapeutics. Joint health issues are predicted to affect
nearly 1 in 5 dogs, and the canine joint health supplement market
generates roughly $300 million in annual sales in the US alone.
The research study, a canine whole-blood assay, involves
experimentally inducing a state of inflammation in a process that
mimics the conditions observed in dogs with osteoarthritis, in
order to investigate the anti-inflammatory properties of HEPI's
compounds. Canine osteoarthritis is a complex disease caused
by the degradation of cartilage tissue. The assay measured
Prostaglandin E2 (PGE2), a biological mediator of inflammation and
target for inhibiting aggressive or prolonged immune responses.
The initial results of the study indicate that
naturally-produced HEPI compounds significantly reduce the
stimulated release of PGE2 in canine whole blood -- in other words,
the HEPI compounds were shown to reduce the release of a substance
that contributes to pain and inflammation in osteoarthritis. These
results support prior HEPI research, which demonstrated significant
reduction of acute inflammation in a similar animal model.
These clinically significant results are compelling evidence for
the anti-inflammatory effects of HEPI's compounds, and are another
step in establishing the safety and efficacy of supplements for the
dog joint health market.
Further research with Covance to repeat these findings in a
larger group and to explore the anti-inflammatory mechanisms of
HEPI compounds will be underway shortly. In the interim, these
results and others are being shared with potential development
partners.
"Each step in the process makes a case for the efficacy and
safety of the product," states R&D director Dr. Amy Steffek.
"Each step also adds value to the product concept."
The Company has also commenced a follow-on study with the
University of Missouri to further substantiate the positive effects
of its bioactive compounds in supporting canine joint health.
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTCQB: HEPI) is a
Michigan-based biotech company engaged in the investigation of the
health benefits of bioactive compounds derived from its proprietary
algal cultures, and the development of natural bioactive compounds
for use as dietary supplements and food ingredients, as well as
biologics and synthetic candidates for medicinal and pharmaceutical
applications in humans and animals, specifically focused on
autoimmune modulation.
Safe Harbor Statement Except for any historical information, the
matters discussed in this press release contain forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements involve risks and uncertainties. A
number of factors could cause actual results to differ from those
indicated in the forward-looking statements, including the timing
of completion of a trial, actual future clinical trial results
being different than the results the company has obtained to date,
and the company's ability to secure funding. Such statements are
subject to a number of assumptions, risks and uncertainties.
Readers are cautioned that such statements are not guarantees of
future performance and those actual results or developments may
differ materially from those set forth in the forward-looking
statements. The company undertakes no obligation to publicly update
or revise forward-looking statements, whether as a result of new
information or otherwise.
Zivo Bioscience (QB) (USOTC:ZIVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zivo Bioscience (QB) (USOTC:ZIVO)
Historical Stock Chart
From Apr 2023 to Apr 2024